Clinical trials: Immune Reconstitution
Lymphoma, Multiple Myeloma
CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig
This is a prospective, interventional study administering 2 doses of the experimental vaccine (CMV-MVA Triplex) to 20 evaluable patients (10 CMV-seropositive and 10 seronegative) undergoing autologous hematopoietic cell…
- Trial name
- NCT03383055
- Testing
- CMV-MVA Triplex Vaccine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Myelodysplastic Syndrome, Acute Lymphocytic Leukemia
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
Background: One way to treat certain cancers of the blood and immune system is to give a patient stem cells from the bone marrow of a donor whose genes are very similar but not identical to the patients.
- Conditions
- Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT01338987
- Testing
- First Allogeneic Bone Marrow Transplant (BMT), Leuprolide, 18F FLT
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections, HIV
Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral Treatment
This study will evaluate whether interleukin-7 (IL-7) a drug similar to the natural IL-7 protein produced by the body, is safe to use in people infected with HIV. IL-7 is important in immune system function.
- Trial name
- NCT00105417
- Testing
- IL-7
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hematologic Malignancy
Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)
This is an open-labelled and non-controlled Phase I/II clinical trial, evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB)…
- Trial name
- HTLP-ONCO (NCT04707300)
- Testing
- Human T Lymphoid Progenitor (HTLP) injection
- Where
- 5 sites in France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
AML, CML
Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant
This is a phase I inter-patient dose escalation open labeled study assessing multiple doses of CYT107 in patients of at least 15 years of age, who are recipients of HLA matched ex vivo T cell depleted bone marrow or peripheral…
- Conditions
- AML, CML, MDS
- Trial name
- NCT00684008
- Testing
- CYT107 - Recombinant glycosylated human interleukin 7., rhIL-7 (CYT107)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Cytheris, Inc.
Hematopoietic Stem Cell Transplantation (HSCT), COVID-19 Vaccines
Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients
COVID-19 vaccinations are predicted to be a huge success in pandemic control. However, the majority of the studies were conducted on healthy individuals, and the efficiency of COVID-19 vaccination in post-transplant patients is…
- Conditions
- Hematopoietic Stem Cell Transplantation (HSCT), COVID-19 Vaccines, Immune System Tolerance
- Trial name
- ESCVHSCT (NCT05185817)
- Testing
- Pasocovac vaccine
- Where
- Iran
- Volunteers
- 100 people
- Sponsor
- Tehran University of Medical Sciences
Human Immunodeficiency Virus, Immune Reconstitution Inflammatory Syndrome
Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART)
Design: Randomized clinical trial involving hospitalized HIV-1 infected children. Children will be randomized to randomized to urgent (<48 hours) versus early antiretroviral therapy (7-14 days). This trial will be unblinded.
- Trial name
- PUSH (NCT02063880)
- Testing
- Urgent ART, Early ART
- Where
- 4 sites in Kenya
- Volunteers
- 183 people
- Sponsor
- University of Washington
Cytomegalovirus Retinitis, HIV Infections
A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effective Anti-HIV Therapy
The purpose of this study is to see if it is safe to stop maintenance therapy in HIV-positive patients with treated and healed CMV retinitis (eye disease) who have responded well to anti-HIV (antiretroviral) therapy.
- Trial name
- NCT00000905
- Where
- 25 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Breast Cancer, Colon Cancer
Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy
Background: Drugs given to treat cancer (chemotherapy) can weaken the human immune system. But it can also become weaker because of aging.
- Conditions
- Breast Cancer, Colon Cancer, Bladder Cancer
- Trial name
- NCT01339000
- Testing
- Glycosylated Recombinant Human Interleukin-7, Diphtheria/Tetanus Vaccine, Polio Vaccine
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
This study will compare an anti-HIV drug combination of protease inhibitor plus a nonnucleoside reverse transcriptase inhibitor (NNRTI) to one that includes three nucleoside reverse transcriptase inhibitors (NRTIs) plus an NNRTI.
- Trial name
- NCT00004855
- Testing
- Lopinavir/Ritonavir, Abacavir sulfate, Nevirapine
- Where
- 23 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Myeloid Leukemia
Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid Leukemia
Multicentric evaluation of the reduction of unrelated cord blood transplantation (UCBT) toxicity by using reduced intensity conditioning (RIC) in patients with acute myeloid leukaemia.UCBT related mortality and morbidity were…
- Trial name
- MINICORD (NCT00797758)
- Testing
- Cord blood transplantation
- Where
- France
- Volunteers
- 76 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV Infection
Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor
This study will continue to follow children who participated in an earlier National Cancer Institute trial of HIV treatment with a protease inhibitor.
- Trial name
- NCT00001826
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
The purpose of this study is to determine whether ATIR is safe and effective in reducing transplant-related mortality and improving overall survival, when infused in patients with a hematologic malignancy following a T-cell…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01794299
- Testing
- ATIR
- Where
- 8 sites in Belgium, Canada and 2 more
- Volunteers
- 31 people
- Sponsor
- Kiadis Pharma
Atopic Dermatitis
Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis
Topical steroid use may lead to skin deterioration and spider veins. This study will examine long-term management of atopic dermatitis (AD) over 12 months with pimecrolimus cream 1% and its effect on skin reconstitution of…
- Trial name
- NCT00367393
- Testing
- Pimecrolimus cream 1%
- Where
- Germany
- Volunteers
- 41 people
- Sponsor
- Novartis
Multiple Sclerosis, Autologous Hematopoietic Stem Cell Transplant
ATLG Levels in Autologous HSCT for Multiple Sclerosis
This is a prospective, observational, biological, multicenter study to investigate IR profile, ATLG dynamics, main HSCT and disease outcomes in MS.
- Conditions
- Multiple Sclerosis, Autologous Hematopoietic Stem Cell Transplant, ATLG
- Trial name
- ATLG-MS (NCT07635693)
- Testing
- ATLG administration
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Ciceri Fabio
Cancer, Neoplasms
Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer
This study evaluates four different doses of ACIT-1 for safety and for the ability to raise effective anti-cancer immune responses in patients with pancreatic and other cancers.
- Trial name
- NCT03096093
- Testing
- ACIT-1
- Where
- 2 sites in United Kingdom
- Volunteers
- 34 people
- Sponsor
- Cancer Vaccines Limited
HIV Infection, HIV Infections
Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration
This pilot study aims to evaluate Maraviroc intensification strategy during 24 weeks in HIV infected patients under efficient (CV< 50 cp/mL), controlled antiretroviral therapy (≥ 6 months) and uncompleted immune restoration…
- Trial name
- 145 MARIMUNO (NCT00944541)
- Testing
- maraviroc
- Where
- France
- Volunteers
- 60 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV
Addition of Raltegravir to Established Antiretroviral Suppressive Therapy
This study will examine whether intensification with raltegravir of a suppressive antiretroviral regimen in HIV infected patients with poor immune restoration has a beneficial effect on cryptic viral replication and the immune…
- Trial name
- NCT01245101
- Testing
- Raltegravir
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Miami
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma
RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Giving vaccine therapy after an autologous stem cell transplant may kill any cancer cells that remain after transplant.
- Conditions
- Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Small Intestine Cancer
- Trial name
- NCT00569309
- Testing
- Streptococcus pneumoniae, laboratory correlative studies, quality-of-life assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia)
PRAISE-IR Versus CIBMTR Controls
The rationale to conduct this RWE study is to provide data to support the safety of CD34 selected grafts versus T replete PBSC transplants to address concerns about increased TRM in CD34 selected graft recipients.
- Conditions
- ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome)
- Trial name
- NCT07717164
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Miltenyi Biomedicine GmbH